CN100579579C - 抗癌及抗感染性疾病组合物及其使用方法 - Google Patents

抗癌及抗感染性疾病组合物及其使用方法 Download PDF

Info

Publication number
CN100579579C
CN100579579C CN200380104308A CN200380104308A CN100579579C CN 100579579 C CN100579579 C CN 100579579C CN 200380104308 A CN200380104308 A CN 200380104308A CN 200380104308 A CN200380104308 A CN 200380104308A CN 100579579 C CN100579579 C CN 100579579C
Authority
CN
China
Prior art keywords
cell
pathogenic
virus
baculovirus
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200380104308A
Other languages
English (en)
Chinese (zh)
Other versions
CN1717250A (zh
Inventor
W·M·卡瓦诺
D·L·斯隆
M·L·麦克占
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc, Chiron Corp filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN1717250A publication Critical patent/CN1717250A/zh
Application granted granted Critical
Publication of CN100579579C publication Critical patent/CN100579579C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200380104308A 2002-10-01 2003-10-01 抗癌及抗感染性疾病组合物及其使用方法 Expired - Fee Related CN100579579C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/416,660 2002-10-01
US60/414,649 2002-10-01
US41666002P 2002-10-07 2002-10-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910253113A Division CN101721697A (zh) 2002-10-01 2003-10-01 抗癌及抗感染性疾病组合物及其使用方法

Publications (2)

Publication Number Publication Date
CN1717250A CN1717250A (zh) 2006-01-04
CN100579579C true CN100579579C (zh) 2010-01-13

Family

ID=32069951

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200380104308A Expired - Fee Related CN100579579C (zh) 2002-10-01 2003-10-01 抗癌及抗感染性疾病组合物及其使用方法

Country Status (7)

Country Link
US (1) US7122546B2 (https=)
EP (1) EP1549636A1 (https=)
JP (1) JP2006504714A (https=)
CN (1) CN100579579C (https=)
AU (1) AU2003267722A1 (https=)
CA (1) CA2495698A1 (https=)
WO (1) WO2004031174A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003276514A1 (en) * 2002-11-08 2004-06-07 Neurogen Corporation 4-imidazol-1-ylmethyl-pyrimidine derivatives_as ligands for gabaa receptors
EP1594848A1 (en) 2003-02-19 2005-11-16 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
BRPI0412908A (pt) * 2003-07-25 2006-09-26 Neurogen Corp composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção ou demência de alzheimer, para potenciar um efeito terapêutico de um agente do cns, para melhorar a memória de curta duração em um paciente, para alterar a atividade de transdução de sinal de receptor gabaa, e para determinar a presença ou ausência de receptor gabaa em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal
BRPI0510929A (pt) 2004-06-18 2007-07-17 Chiron Corp derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer
WO2008086122A2 (en) 2007-01-05 2008-07-17 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
KR20090111847A (ko) 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Ｍｅｋ 억제제
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
RU2705556C2 (ru) * 2012-12-21 2019-11-07 Келверум Инк. Нереплицируемые происходящие от вирусов частицы и их применение
JP7113023B2 (ja) 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002557A2 (en) * 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
WO2004041809A2 (en) * 2002-05-08 2004-05-21 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
AU2003276514A1 (en) 2002-11-08 2004-06-07 Neurogen Corporation 4-imidazol-1-ylmethyl-pyrimidine derivatives_as ligands for gabaa receptors
US20060247245A1 (en) 2003-05-05 2006-11-02 Yuelian Xu Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US6451303B1 (en) * 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect of different baculovirus inactivation procedures on theintegrity and immunogenicity of porcine parvovirus-likeparticles. Rueda et al.Vaccine,Vol.19. 2001 *
Photochemical inactivation of recombinant baculovirus. Weightman et al.Journal of Virological Methods,Vol.81. 1999 *

Also Published As

Publication number Publication date
WO2004031174A1 (en) 2004-04-15
CN1717250A (zh) 2006-01-04
WO2004031174A8 (en) 2005-04-21
EP1549636A1 (en) 2005-07-06
JP2006504714A (ja) 2006-02-09
CA2495698A1 (en) 2004-04-15
AU2003267722A8 (en) 2004-04-23
US7122546B2 (en) 2006-10-17
AU2003267722A1 (en) 2004-04-23
US20040077653A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2009230821B2 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
US6342216B1 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
CN102268454B (zh) 一种psma重组腺相关病毒载体及其构建方法与应用
JP6698881B2 (ja) 新規の免疫刺激性ベクター系
US20100172877A1 (en) Compositions and methods of use of an oncolytic vesicular stomatitis virus
WO2019062250A1 (zh) 包含分离的重组溶瘤腺病毒和nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
CN100579579C (zh) 抗癌及抗感染性疾病组合物及其使用方法
US9241998B2 (en) Methods and compositions for treatment of cancer using oncolytic RSV activity
ES2660577T3 (es) Células que expresan características y propiedades citolíticas de Th1
CN100488567C (zh) 癌基因治疗药物
JP4708027B2 (ja) 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
CN119101665A (zh) 一种重组溶瘤病毒VSV-sPD1IL15RaIL15及构建方法和应用
US6872385B2 (en) Adjuvant preparation for the induction of specific immunity
RU2447899C2 (ru) Композиция для лечения гепатита с и способ лечения гепатита с
ES2313723T3 (es) Vacunas del virus de la inmunodeficiencia humana y agentes terapeuticos que contienen mutantes de delecion de nef de hiv-1 deteriorados en replicacion.
JP2006517184A5 (https=)
WO2004037182A2 (en) Active specific immunotherapy of cancer metastasis
US20070264281A1 (en) Vaccination Vectors Derived From Lymphotropic Human Herpes Viruses 6 and 7
Dorostkar et al. An endogenous immune adjuvant released by necrotic cells for enhancement of DNA vaccine potency
Liu et al. Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX
Berthold et al. Intrinsic interference caused by hepatitis sera
Brenner et al. T-Cell Therapies for EBV-Associated Malignancies
Immunotherapy Divergent Roles for CD4

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100113

Termination date: 20121001